NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
AMICAR (aminocaproic acid) by KalVista Pharmaceuticals is clinical pharmacology the fibrinolysis-inhibitory effects of amicar appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Approved for anemia. First approved in 1964.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMICAR (aminocaproic acid) is a fibrinolysis inhibitor that works by blocking plasminogen activators and antiplasmin activity to reduce excessive bleeding. It is indicated for anemia management in patients experiencing abnormal fibrinolysis. The drug is administered by injection and has a rapid onset with a 2-hour elimination half-life.
$0.06MPart D
LOE ApproachingDeclining
As AMICAR approaches loss of exclusivity with minimal current Medicare spending ($60K in 2023), the brand team is likely small and focused on defensive strategies rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The fibrinolysis-inhibitory effects of AMICAR appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The…
Indications (1)
Worked on AMICAR at KalVista Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.